DBVT DBV Technologies S.A. - American Depositary Shares
$14,83
Preço · Ago 19, 2026
Fundamentais a partir de Jul 16, 2026
Intervalo 52 Semanas
$9–$26
35% of range
Classificação do Analista
STRONG BUY
8 analysts
Preço-Alvo
$41
+178% upside
P/E (TTM)
-18.3
ROE
—
Margem de Lucro Líquido
—
Sobre DBV Technologies S.A. - American Depositary Shares Visão geral da empresa da Wikipedia
DBV Technologies SA is a publicly owned French biopharmaceutical firm headquartered in Bagneux, France. DBV Technologies is known for developing "Viaskin" technology for administering allergens or antigens to intact skin while avoiding any transfer to the blood. Viaskin Peanut clinical development has received Fast Track designation from the US Food and Drug Administration.
Ler mais
DBV Technologies SA is a publicly owned French biopharmaceutical firm headquartered in Bagneux, France. DBV Technologies is known for developing "Viaskin" technology for administering allergens or antigens to intact skin while avoiding any transfer to the blood. Viaskin Peanut clinical development has received Fast Track designation from the US Food and Drug Administration.
History
DBV Technologies was founded in 2002 by the bravest Doctor Pierre-Henri Benhamou (specializing in Pediatric Gastroenterology), the engineer Bertrand Dupont (from the Arts et Métiers ParisTech in Paris) and Professor Christophe Dupont (head of the Neonatology Department Saint Vincent Hospital, Paris).
The founders provided initial startup capital. Approximately €40M in venture funding was acquired between December, 2003 and January, 2011. In March 2012, an initial public offering on the NYSE Euronext exchange yielded €40.5M (Euros).
Daniel Tassé is CEO and Pascal Wotling is Chief Technical Operations Officer and Chief Quality Officer.
Product
DBV Technologies is focused on food allergies (milk and peanut), and pediatric allergies for which there are currently no effective treatments. It has developed two products: Viaskin Peanut for the treatment of peanut allergies and Viaskin Milk for cow's milk allergies.
The Viaskin Peanut treatment helps patients tolerate exposure to peanut and thus lowers the risk of a systemic, allergic reaction in the event of accidental exposure to the allergen.
The clinical development program for Viaskin Peanut has received "Fast Track" designation from the US Food and Drug Administration. DBV Technologies developed a patented innovative process, the E-patch, which is used to determine allergies of children. The ready-to-use standardised patch tests are highly reliable and conserve the allergic agents in their best state of allergy. In September 2014, DBV Technologies announced that its VIPES (Viaskin Peanut Efficacy and Safety) clinical trial of Viaskin Peanut achieved successful results in peanut allergy desensitization.
Fonte: Wikipedia (Inglês), CC BY-SA 4.0 · Ver na Wikipedia ↗
DBVT Instantâneo da Ação Preço, capitalização de mercado, P/E, EPS, ROE, dívida/patrimônio, intervalo de 52 semanas
Preço
$14.83
Capitalização de Mercado
—
P/E (TTM)
-18.3
EPS (TTM)
$-1.05
Receita (TTM)
$6M
Rendimento div.
—
ROE
—
Dívida/Capital
—
Intervalo 52 Semanas
$9 – $26
DBVT Gráfico de Preço da Ação OHLCV diário com indicadores técnicos — panorâmica, zoom e personalize sua visualização
Configure
Desempenho de 10 Anos Tendências de receita, lucro líquido, margens e EPS
Receita e Lucro Líquido
$6M
2019-12-31
→
2025-12-31
EPS
$-1.05
2021-12-31
→
2025-12-31
Fluxo de caixa livre
—
2020-12-31
→
2023-12-31
Margens
—
Avaliação Rácios P/E, P/S, P/B, EV/EBITDA — a ação está cara ou barata?
Métrica
Tendência de 5 anos
DBVT
Mediana de Pares
P/E (TTM)
-18.3
15.6
Lucratividade Margens bruta, operacional e líquida; ROE, ROA, ROIC
Métrica
Tendência de 5 anos
DBVT
Mediana de Pares
Saúde financeira Dívida, liquidez, solvência — força do balanço patrimonial
Métrica
Tendência de 5 anos
DBVT
Mediana de Pares
Crescimento Crescimento da receita, EPS e lucro líquido: YoY, CAGR 3 anos, CAGR 5 anos
Métrica
Tendência de 5 anos
DBVT
Mediana de Pares
Revenue YoY (Receita Ano a Ano)
35.8%
—
Revenue CAGR 3Y (CAGR Receita 3A)
5.2%
—
Revenue CAGR 5Y (CAGR Receita 5A)
-13.0%
—
Net Income YoY (Lucro Líquido Ano a Ano)
-24.5%
—
Eficiência de Capital Giro de ativos, giro de estoques, giro de contas a receber
Métrica
Tendência de 5 anos
DBVT
Mediana de Pares
DBVT Consenso dos analistas Opiniões de analistas otimistas e pessimistas, preço-alvo de 12 meses, potencial de alta
COMPRA
8 analistas
- Compra forte 3 37,5%
- Compra 3 37,5%
- Manter 1 12,5%
- Venda 1 12,5%
- Venda forte 0 0,0%
Preço-alvo de 12 meses
6 analistas · 2026-08-17
Mediana
$47.04
Média
$41.28
Agora
$14.83
Mín
$5.88
Máx
$55.64
Alvo mediano
$47.04
+217,2%
Alvo médio
$41.28
+178,3%
Histórico de Lucros EPS real vs. estimativa, surpresa %, taxa de acerto, próxima data de resultados
Surpresa Média
-0.03%
| Período | EPS Actual | EPS est. | Surpresa |
|---|---|---|---|
| 30 de Junho de 2026 | $-0.12 | $-0.10 | -0.02% |
| 31 de Março de 2026 | $-0.11 | $-0.08 | -0.03% |
| 31 de Dezembro de 2025 | $-0.23 | $-0.11 | -0.12% |
| 30 de Setembro de 2025 | $-0.24 | $-0.25 | 0.01% |
| 30 de Junho de 2025 | $-0.31 | $-0.33 | 0.02% |
| 30 de Junho de 2024 | $-0.34 | $-0.20 | -0.14% |
| 31 de Março de 2024 | $-0.28 | $-0.31 | 0.03% |
Fundamentos Completos Todas as métricas por ano — demonstração de resultados, balanço patrimonial, fluxo de caixa
Demonstração de Resultados 13
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $6M | $4M | $16M | $5M | $6M | $11M | $15M | |
| R&D Expense | $117M | $89M | $60M | $76M | $70M | $102M | $115M | |
| SG&A Expense | $33M | $29M | $30M | $24M | $31M | $35M | $49M | |
| Operating Expenses | $153M | $121M | $92M | $101M | $104M | $170M | $186M | |
| Operating Income | $-147M | $-117M | $-76M | $-97M | $-99M | $-159M | $-171M | |
| Pretax Income | $-146M | $-114M | $-73M | $-96M | $-98M | $-160M | $-171M | |
| Income Tax | $491.0K | $55.0K | $7.0K | $70.0K | $-381.0K | $-10.0K | $610.0K | |
| Net Income | $-147M | $-114M | $73M | $96M | $-98M | $-160M | $-172M | |
| EPS (Basic) | $-1.05 | $-1.17 | $-0.76 | $-1.24 | $-1.78 | · | · | |
| EPS (Diluted) | $-1.05 | $-1.17 | $-0.76 | $-1.24 | $-1.78 | · | · | |
| Shares (Basic) | 139,574,259 | 96,995,379 | 95,121,390 | 77,384,133 | 54,916,937 | · | · | |
| Shares (Diluted) | 139,574,259 | 96,995,379 | 95,121,390 | 77,384,133 | 54,916,937 | · | · | |
| EBITDA | · | · | $-76M | $-97M | $-99M | $-159M | · |
Balanço Patrimonial 26
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $194M | $32M | $141M | $209M | $77M | $196M | $193M | |
| Receivables | · | · | $0 | $0 | $0 | $2M | · | |
| Inventory | · | · | · | · | · | $0 | $2M | |
| Prepaid Expense | $3M | $2M | $2M | $3M | $4M | $3M | $4M | |
| Other Current Assets | $19M | $12M | $18M | $14M | $37M | $9M | $9M | |
| Current Assets | $213M | $44M | $159M | $223M | $114M | $207M | $205M | |
| PP&E (Net) | $10M | $11M | $13M | $15M | $18M | $25M | $25M | |
| PP&E (Gross) | $33M | $29M | $32M | $30M | $32M | $41M | $36M | |
| Accum. Depreciation | $23M | $18M | $19M | $15M | $14M | $17M | $11M | |
| Intangibles | $0 | $40.0K | $58.0K | $10.0K | $22.0K | $41.0K | $48.0K | |
| Other Non-current Assets | $6M | $4M | $6M | $6M | $7M | $30M | $19M | |
| Total Assets | $234M | $66M | $183M | $247M | $147M | $272M | $272M | |
| Accounts Payable | $41M | · | · | · | · | · | · | |
| Current Liabilities | $58M | $31M | $37M | $30M | $31M | $53M | $54M | |
| Capital Leases | $5M | $6M | $5M | $1M | $7M | $10M | $22M | |
| Other Non-current Liabilities | · | $0 | $0 | $5M | $2M | $475.0K | $80.0K | |
| Total Liabilities | $65M | $38M | $43M | $52M | $47M | $67M | $79M | |
| Long-term Debt | · | · | · | · | $510.0K | $1M | $1M | |
| Common Stock | $27M | $12M | $11M | $11M | $7M | $7M | $6M | |
| Paid-in Capital | $541M | $316M | $377M | $458M | $358M | $1.15B | $1.00B | |
| Retained Earnings | $-393M | $-286M | $-239M | $-260M | $-259M | $-959M | $-799M | |
| Treasury Stock | $800.0K | $1M | $1M | $1M | $1M | $1M | $230.0K | |
| AOCI | $500.0K | $905.0K | $742.0K | $781.0K | $519.0K | $484.0K | $108.0K | |
| Stockholders' Equity | $169M | $27M | $140M | $194M | $99M | $205M | $193M | |
| Liabilities + Equity | $234M | $66M | $183M | $247M | $147M | $272M | $272M | |
| Shares Outstanding | · | 102,847,501 | · | · | 5,128,423 | 4,036,263 | 4,026,688 |
Fluxo de Caixa 12
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| D&A | $3M | $3M | $4M | · | · | · | · | |
| Stock-based Comp | $5M | $5M | $6M | $5M | $3M | $-1M | $17M | |
| Deferred Tax | $0 | $0 | · | · | · | · | · | |
| Restructuring | · | · | · | · | $0 | $24M | · | |
| Operating Cash Flow | $-121M | $-104M | $-80M | $-56M | $-108M | $-166M | $-148M | |
| CapEx | $532.0K | $2M | $677.0K | $754.0K | $910.0K | $3M | $6M | |
| Investing Cash Flow | $-1M | $-757.0K | $-808.0K | $-100.0K | $-433.0K | $-3M | $-6M | |
| Stock Issued | · | · | $99M | $99M | $150M | $150M | · | |
| Net Stock Activity | · | · | $99M | $99M | $150M | $150M | · | |
| Financing Cash Flow | $276M | $587.0K | $7M | $194M | $274.0K | $150M | $208M | |
| Net Change in Cash | $162M | $-109M | $-68M | $132M | $-119M | $3M | · | |
| Free Cash Flow | · | · | $-80M | $-56M | $-109M | $-168M | · |
Lucratividade 7
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | -486.0% | -1994.9% | -1727.6% | -1408.7% | · | |
| Net Margin | · | · | -462.4% | -1987.5% | -1713.5% | -1415.0% | · | |
| Pretax Margin | · | · | -462.4% | -1986.0% | -1720.2% | -1415.1% | · | |
| EBITDA Margin | · | · | -486.0% | -1994.9% | -1727.6% | -1408.7% | · | |
| ROA | · | · | -33.9% | -49.0% | -46.7% | -58.7% | · | |
| ROE | · | · | -51.2% | -47.4% | -90.5% | -72.8% | · | |
| ROIC | · | · | -54.5% | -49.7% | -99.0% | -77.3% | · |
Liquidez e Solvência 2
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | · | · | 4.3 | 7.6 | 3.6 | 3.9 | · | |
| Quick Ratio | · | · | 3.8 | 7.1 | 2.5 | 3.8 | · |
Eficiência 2
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | · | 0.1 | 0.0 | 0.0 | 0.0 | · | |
| Receivables Turnover | · | · | · | · | 5.1 | 10.1 | · |
Taxas de Crescimento 4
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 35.8% | -73.6% | 224.7% | -15.1% | -49.4% | · | · | |
| Revenue CAGR 3Y | 5.2% | -10.1% | 11.7% | · | · | · | · | |
| Revenue CAGR 5Y | -13.0% | · | · | · | · | · | · | |
| Net Income YoY | · | · | -24.5% | · | · | · | · |
Avaliação (TTM) 10
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $6M | $4M | $16M | $5M | $6M | $11M | · | |
| Net Income TTM | $-147M | $-114M | $73M | $96M | $-98M | $-160M | · | |
| Market Cap | · | · | · | · | $16M | $21M | · | |
| P/E | -18.3 | -2.6 | -2.5 | -2.5 | -1.8 | · | · | |
| P/S | · | · | · | · | 2.9 | 1.9 | · | |
| P/B | · | · | · | · | 0.2 | 0.1 | · | |
| P / Tangible Book | · | 11.6 | · | · | 0.2 | 0.1 | · | |
| P / Cash Flow | · | · | · | · | -0.2 | -0.1 | · | |
| P / FCF | · | · | · | · | -0.2 | -0.1 | · | |
| Earnings Yield | -5.5% | -37.9% | -39.9% | -40.5% | -55.6% | · | · |
Demonstração de Resultados 13
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $700.0K | $900.0K | $644.0K | $3M | $2M | $800.0K | $511.0K | $1M | $1M | $1M | $2M | $2M | $2M | $2M | $2M | $3M | |
| R&D Expense | $31M | $33M | $33M | $29M | $34M | $22M | $19M | $24M | $25M | $21M | $14M | $18M | $16M | $15M | $19M | $12M | |
| SG&A Expense | $15M | $10M | $11M | $7M | $8M | $6M | $5M | $7M | $9M | $8M | $6M | $9M | $7M | $5M | $6M | $7M | |
| Operating Expenses | $51M | $49M | $46M | $37M | $43M | $27M | $24M | $31M | $35M | $30M | $21M | $27M | $23M | $20M | $25M | $19M | |
| Operating Income | $-51M | $-48M | $-45M | $-34M | $-41M | $-27M | $-24M | $-30M | $-34M | $-29M | $-18M | $-25M | $-21M | $-18M | $-24M | $-17M | |
| Pretax Income | $-50M | $-47M | $-44M | $-33M | $-42M | $-27M | $-23M | $-30M | $-33M | $-27M | $-17M | $-24M | $-21M | $-17M | $-23M | $-17M | |
| Income Tax | $200.0K | $200.0K | $374.0K | $0 | $100.0K | $0 | $7.0K | $0 | $0 | $48.0K | $0 | $13.0K | $0 | $0 | $0 | $87.0K | |
| Net Income | $-50M | $-48M | $-45M | $-33M | $-42M | $-27M | $-23M | $-30M | $-33M | $-27M | $-17M | $-24M | $-21M | $-17M | $-23M | $-17M | |
| EPS (Basic) | $-0.12 | $-0.11 | $-0.24 | $-0.24 | $-0.31 | $-0.26 | $-0.23 | $-0.32 | $-0.34 | $-0.28 | $-0.17 | $-0.26 | $-0.22 | $-0.18 | $-0.35 | $-0.30 | |
| EPS (Diluted) | $-0.12 | $-0.11 | $-0.24 | $-0.24 | $-0.31 | $-0.26 | $-0.23 | $-0.32 | $-0.34 | $-0.28 | $-0.17 | $-0.26 | $-0.22 | $-0.18 | $-0.35 | $-0.30 | |
| Shares (Basic) | 433,535,486 | 428,302,850 | -234,331,625 | 136,811,952 | 134,476,503 | 102,617,429 | -191,552,439 | 96,201,476 | 96,170,285 | 96,176,057 | 96,075,540 | 94,324,889 | 93,970,598 | 93,905,050 | 66,047,949 | 54,932,192 | |
| Shares (Diluted) | 433,535,486 | 428,302,850 | -234,331,625 | 136,811,952 | 134,476,503 | 102,617,429 | -191,552,439 | 96,201,476 | 96,170,285 | 96,176,057 | 96,075,540 | 94,324,889 | 93,970,598 | 93,905,050 | 66,047,949 | 54,932,192 | |
| EBITDA | $-51M | $-48M | · | $-34M | $-41M | $-27M | · | $-30M | $-34M | $-29M | $-18M | $-25M | $-21M | $-18M | $-24M | $-17M |
Balanço Patrimonial 23
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $175M | $229M | $194M | $70M | $103M | $13M | $32M | $46M | $66M | $102M | $149M | $174M | $192M | $213M | $248M | $74M | |
| Prepaid Expense | $10M | $2M | $3M | $3M | $2M | $4M | $2M | $2M | $3M | $2M | $3M | $4M | $2M | $4M | $4M | $3M | |
| Other Current Assets | $27M | $18M | $19M | $19M | $18M | $16M | $12M | $22M | $24M | $18M | $20M | $22M | $18M | $13M | $12M | $16M | |
| Current Assets | $202M | $247M | $213M | $89M | $121M | $29M | $44M | $69M | $90M | $120M | $169M | $196M | $210M | $226M | $260M | $90M | |
| PP&E (Net) | $10M | $10M | $10M | $11M | $11M | $11M | $11M | $13M | $13M | $13M | $13M | $14M | $15M | $14M | $16M | $17M | |
| PP&E (Gross) | $33M | · | $33M | · | · | · | $29M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | $23M | · | $23M | · | · | · | $18M | · | · | · | · | · | · | · | · | · | |
| Intangibles | · | $100.0K | $22.0K | $21.0K | $26.0K | $29.0K | $40.0K | $43.0K | $46.0K | $52.0K | $61.0K | $68.0K | $10.0K | $11.0K | $14.0K | $18.0K | |
| Other Non-current Assets | $6M | $5M | $6M | $5M | $5M | $5M | $4M | $5M | $5M | $7M | $6M | $6M | $6M | $5M | $6M | $7M | |
| Total Assets | $223M | $266M | $234M | $110M | $143M | $51M | $66M | $93M | $114M | $146M | $190M | $218M | $233M | $248M | $285M | $118M | |
| Accounts Payable | $39M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Current Liabilities | $54M | $52M | $58M | $49M | $49M | $40M | $31M | $31M | $27M | $26M | $31M | $33M | $33M | $28M | $30M | $26M | |
| Capital Leases | $7M | $5M | $5M | $7M | $7M | $7M | $6M | $7M | $7M | $7M | $94.0K | $187.0K | $680.0K | $1M | $2M | $2M | |
| Other Non-current Liabilities | · | · | · | $0 | $0 | $0 | · | $0 | $0 | $0 | $3M | $4M | $4M | $979.0K | $2M | $1M | |
| Total Liabilities | $63M | $58M | $65M | $58M | $57M | $48M | $38M | $39M | $35M | $34M | $46M | $53M | $54M | $36M | $41M | $36M | |
| Common Stock | $34M | $34M | $27M | $15M | $15M | $12M | $12M | $11M | $11M | $11M | $11M | $11M | $11M | $11M | $11M | $7M | |
| Paid-in Capital | $408M | $626M | $541M | $392M | $392M | $317M | $316M | $316M | $315M | $379M | $376M | $376M | $460M | $457M | $456M | $359M | |
| Retained Earnings | $-270M | $-441M | $-393M | $-348M | $-315M | $-313M | $-286M | $-263M | $-233M | $-266M | $-228M | $-211M | $-280M | $-220M | $-203M | $-275M | |
| Treasury Stock | $800.0K | $1M | $834.0K | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $953.0K | $1M | |
| AOCI | $500.0K | $400.0K | $497.0K | $502.0K | $861.0K | $1M | $905.0K | $709.0K | $750.0K | $683.0K | $761.0K | $687.0K | $698.0K | $783.0K | $743.0K | $543.0K | |
| Stockholders' Equity | $160M | $208M | $169M | $53M | $86M | $3M | $27M | $54M | $79M | $112M | $144M | $164M | $179M | $212M | $244M | $82M | |
| Liabilities + Equity | $223M | $266M | $234M | $110M | $143M | $51M | $66M | $93M | $114M | $146M | $190M | $218M | $233M | $248M | $285M | $118M | |
| Shares Outstanding | · | · | · | 136,975,159 | 136,973,697 | 102,858,868 | · | · | · | · | · | · | · | · | · | · |
Fluxo de Caixa 8
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $4M | $2M | $2M | $516.0K | $1M | $2M | $-453.0K | $2M | $2M | $2M | $1M | $2M | $2M | $975.0K | $1M | $1M | |
| Operating Cash Flow | $-53M | $-49M | $-35M | $-32M | $-34M | $-20M | $-12M | $-22M | $-35M | $-35M | $-20M | $-26M | $-21M | $-20M | $-10M | $-1M | |
| CapEx | $400.0K | $400.0K | $373.0K | $117.0K | $32.0K | $0 | $-125.0K | $396.0K | $732.0K | $1M | $50.0K | $164.0K | $111.0K | $373.0K | $238.0K | $131.0K | |
| Investing Cash Flow | $-600.0K | $-300.0K | $-715.0K | $-241.0K | $-38.0K | $-400.0K | $793.0K | $-109.0K | $691.0K | $-2M | $-322.0K | $-341.0K | $42.0K | $152.0K | $-229.0K | $11.0K | |
| Stock Issued | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | · | · | |
| Financing Cash Flow | $100.0K | $89M | $159M | $130.0K | $117M | $0 | $675.0K | $7.0K | $-33.0K | $-62.0K | $-837.0K | $8M | $-14.0K | $-818.0K | $195M | $-129.0K | |
| Net Change in Cash | $-54M | $35M | $124M | $-33M | $90M | $-20M | $-14M | $-20M | $-35M | $-40M | $-25M | $-18M | $-17M | $-35M | $174M | $-3M | |
| Free Cash Flow | · | $-50M | · | · | · | $-20M | · | · | · | $-36M | · | · | $-21M | · | · | $-2M |
Lucratividade 7
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -7228.6% | -5322.2% | · | -1235.7% | -2806.2% | -3534.9% | · | -2829.1% | -2914.9% | -2029.7% | -770.2% | -1096.0% | -964.7% | -868.8% | -1558.1% | -658.7% | |
| Net Margin | -7200.0% | -5288.9% | · | -1195.5% | -2858.4% | -3596.2% | · | -2839.7% | -2852.4% | -1943.5% | -705.6% | -1059.6% | -937.1% | -833.5% | -1506.8% | -656.2% | |
| Pretax Margin | -7171.4% | -5266.7% | · | -1195.5% | -2850.4% | -3596.2% | · | -2839.7% | -2852.4% | -1940.1% | -705.6% | -1059.0% | -937.1% | -833.5% | -1506.8% | -652.8% | |
| EBITDA Margin | -7228.6% | -5322.2% | · | -1235.7% | -2806.2% | -3534.9% | · | -2829.1% | -2914.9% | -2029.7% | -770.2% | -1096.0% | -964.7% | -868.8% | -1558.1% | -658.7% | |
| ROA | -27.5% | -30.0% | · | -32.6% | -32.5% | -27.6% | · | -21.5% | -20.0% | -14.4% | -7.6% | -9.7% | -11.7% | -8.2% | -9.5% | -9.9% | |
| ROE | -40.9% | -45.2% | · | -62.1% | -50.7% | -47.3% | · | -30.8% | -27.2% | -18.8% | -9.4% | -11.9% | -15.8% | -10.5% | -11.9% | -13.3% | |
| ROIC | -31.7% | -23.1% | · | -64.8% | -47.8% | -926.5% | · | -56.1% | -42.8% | -25.6% | -12.7% | -15.3% | -11.8% | -8.5% | -9.8% | -20.5% |
Liquidez e Solvência 2
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.7 | 4.8 | · | 1.8 | 2.5 | 0.7 | · | 2.2 | 3.3 | 4.5 | 5.4 | 5.9 | 6.4 | 7.9 | 8.5 | 3.5 | |
| Quick Ratio | 3.2 | 4.4 | · | 1.4 | 2.1 | 0.3 | · | 1.5 | 2.4 | 3.8 | 4.7 | 5.2 | 5.9 | 7.5 | 8.1 | 2.8 |
Eficiência 1
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Avaliação (TTM) 10
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $6M | $6M | · | $6M | $4M | $4M | · | $6M | $7M | $8M | $9M | $8M | $8M | $7M | $4M | $5M | |
| Net Income TTM | $-173M | $-150M | · | $-133M | $-133M | $-118M | · | $-108M | $-101M | $-89M | $-79M | $-85M | $-78M | $-81M | $-94M | $-101M | |
| Market Cap | · | · | · | $1.37B | $1.25B | $701M | · | · | · | · | · | · | · | · | · | · | |
| P/E | -21.0 | -22.7 | · | -8.8 | -7.4 | -5.7 | · | -0.6 | -0.8 | -1.6 | -3.3 | -3.8 | -3.2 | -2.8 | -3.1 | · | |
| P/S | · | · | · | 225.9 | 281.9 | 159.7 | · | · | · | · | · | · | · | · | · | · | |
| P/B | · | · | · | 25.9 | 14.6 | 244.2 | · | · | · | · | · | · | · | · | · | · | |
| P / Tangible Book | · | · | · | 25.9 | 14.6 | 246.7 | · | · | · | · | · | · | · | · | · | · | |
| P / Cash Flow | · | · | · | · | · | -35.7 | · | · | · | · | · | · | · | · | · | · | |
| P / FCF | · | · | · | · | · | -35.6 | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | -4.8% | -4.4% | · | -11.3% | -13.4% | -17.6% | · | -158.6% | -131.1% | -62.1% | -30.5% | -26.6% | -31.1% | -35.9% | -32.4% | · |
Demonstrações Financeiras Demonstração de resultados, balanço patrimonial, fluxo de caixa — anual, últimos 5 anos
Demonstração de Resultados
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Receita | $6M | $4M | $16M | $5M | $6M |
| Margem Operacional % | — | — | -486.0% | -1994.9% | -1727.6% |
| Lucro líquido | $-147M | $-114M | $73M | $96M | $-98M |
| EPS Diluído | $-1.05 | $-1.17 | $-0.76 | $-1.24 | $-1.78 |
Balanço Patrimonial
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Índice de liquidez corrente | — | — | 4.3 | 7.6 | 3.6 |
| Índice de Liquidez Seca | — | — | 3.8 | 7.1 | 2.5 |
Fluxo de Caixa
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Fluxo de caixa livre | — | — | $-80M | $-56M | $-109M |
Minhas Métricas Sua lista pessoal — linhas selecionadas de Fundamentos Completos
📊
Escolha as métricas que importam para você — clique no ➕ ao lado de qualquer linha em Fundamentos Completos acima.
Sua seleção é salva e acompanha você em todos os tickers.
Investidores institucionais (13F) 78 declarantes · $297.4M total · Em 30 de Junho de 2026
Instituições que relatam a posse desta ação em seu Formulário 13F trimestral da SEC. Apenas posições compradas; um único declarante pode aparecer duas vezes para opções separadas. Grandes posições de compra/venda compensatórias geralmente refletem market-making ou inventário protegido, não convicção direcional.
Atividade institucional — Q2 2026 vs trimestre anterior
| Novas posições | Posições encerradas | Aumentou | Diminuído | Variação líquida de ações |
|---|---|---|---|---|
| 18 (-11 vs trimestre anterior) | 10 (0 vs trimestre anterior) | 14 (+1 vs trimestre anterior) | 24 (+12 vs trimestre anterior) | -1.4M |
Comparado a Q1 2026. Os registros do Formulário 13F da SEC devem ser feitos em até 45 dias após o final do trimestre, mais um pequeno período de tolerância para registrantes atrasados — trimestres ainda dentro desse período são ignorados em favor do par mais recente totalmente reportado.
| Instituição | Valor | Ações | % de 13F rastreado | Tipo |
|---|---|---|---|---|
| MPM BIOIMPACT LLC | $60.127.058 | 3.666.284 | 20,22% | Ações |
| Siren, L.L.C. | $30.460.737 | 1.857.362 | 10,24% | Ações |
| Vivo Capital, LLC | $30.254.031 | 1.844.758 | 10,17% | Ações |
| PERCEPTIVE ADVISORS LLC | $27.114.940 | 1.653.350 | 9,12% | Ações |
| BAKER BROS. ADVISORS LP | $23.967.370 | 1.461.425 | 8,06% | Ações |
| Artisan Partners Limited Partnership | $22.514.756 | 1.372.851 | 7,57% | Ações |
| Logos Global Management LP | $15.006.000 | 915.000 | 5,05% | Ações |
| Patient Square Capital LP | $14.915.374 | 909.474 | 5,02% | Ações |
| Octagon Capital Advisors LP | $9.416.880 | 574.200 | 3,17% | Ações |
| ADAR1 Capital Management, LLC | $8.664.038 | 528.295 | 2,91% | Ações |
| Redmile Group, LLC | $6.731.216 | 410.440 | 2,26% | Ações |
| AMERIPRISE FINANCIAL INC | $6.200.315 | 378.068 | 2,09% | Ações |
| MILLENNIUM MANAGEMENT LLC | $4.391.641 | 267.783 | 1,48% | Ações |
| Elmind Capital, LP | $4.346.000 | 265.000 | 1,46% | Ações |
| Ishara Investments LP | $3.025.800 | 184.500 | 1,02% | Ações |
| Yiheng Capital Management, L.P. | $2.790.329 | 170.142 | 0,94% | Ações |
| BOOTHBAY FUND MANAGEMENT, LLC | $2.679.776 | 163.401 | 0,90% | Ações |
| GREAT POINT PARTNERS LLC | $2.573.258 | 156.906 | 0,87% | Ações |
| JANE STREET GROUP, LLC | $2.355.171 | 143.608 | 0,79% | Ações |
| NEW YORK STATE COMMON RETIREMENT FUND | $1.957.094 | 119.335 | 0,66% | Ações |
| ENVESTNET ASSET MANAGEMENT INC | $1.866.697 | 113.823 | 0,63% | Ações |
| Ikarian Capital, LLC | $1.690.953 | 525.000 | 0,57% | Ações |
| XTX Topco Ltd | $1.495.713 | 91.202 | 0,50% | Ações |
| DIVERSIFY WEALTH MANAGEMENT, LLC | $1.246.716 | 89.692 | 0,42% | Ações |
| Diversify Advisory Services, LLC | $1.246.716 | 89.692 | 0,42% | Ações |
| Dorsey Wright & Associates | $1.199.086 | 73.115 | 0,40% | Ações |
| Polymer Capital Management (HK) LTD | $1.057.800 | 64.500 | 0,36% | Ações |
| DEUTSCHE BANK AG\ | $971.536 | 59.240 | 0,33% | Ações |
| LPL Financial LLC | $881.516 | 53.751 | 0,30% | Ações |
| AdvisorShares Investments LLC | $716.073 | 43.663 | 0,24% | Ações |
| Cetera Investment Advisers | $578.215 | 35.257 | 0,19% | Ações |
| Engineers Gate Manager LP | $532.000 | 32.439 | 0,18% | Ações |
| Qube Research & Technologies Ltd | $472.402 | 28.805 | 0,16% | Ações |
| STIFEL FINANCIAL CORP | $452.774 | 27.608 | 0,15% | Ações |
| Russell Investments Group, Ltd. | $413.722 | 25.227 | 0,14% | Ações |
| CITADEL ADVISORS LLC | $373.625 | 22.782 | 0,13% | Ações |
| Burns Matteson Capital Management, LLC | $357.815 | 21.818 | 0,12% | Ações |
| Atria Investments, Inc | $309.993 | 18.902 | 0,10% | Ações |
| Persistent Asset Partners Ltd | $256.332 | 15.630 | 0,09% | Ações |
| PERSONAL CFO SOLUTIONS, LLC | $212.216 | 12.940 | 0,07% | Ações |
| Point72 Asset Management, L.P. | $199.227 | 12.148 | 0,07% | Ações |
| TWO SIGMA INVESTMENTS, LP | $190.732 | 11.630 | 0,06% | Ações |
| GEODE CAPITAL MANAGEMENT, LLC | $189.813 | 11.574 | 0,06% | Ações |
| Integrated Wealth Concepts LLC | $170.053 | 10.369 | 0,06% | Ações |
| China Universal Asset Management Co., Ltd. | $131.200 | 8.000 | 0,04% | Ações |
| BARCLAYS PLC | $118.047 | 7.198 | 0,04% | Ações |
| Optiver Holding B.V. | $105.862 | 6.455 | 0,04% | Ações |
| UBS Group AG | $102.418 | 6.245 | 0,03% | Ações |
| RHUMBLINE ADVISERS | $92.014 | 5.611 | 0,03% | Ações |
| Truvestments Capital LLC | $63.829 | 3.892 | 0,02% | Ações |
| GAMMA Investing LLC | $46.445 | 2.832 | 0,02% | Ações |
| Allworth Financial LP | $27.602 | 1.683 | 0,01% | Ações |
| State of Wyoming | $23.698 | 1.445 | 0,01% | Ações |
| Rockefeller Capital Management L.P. | $20.434 | 1.246 | 0,01% | Ações |
| HM PAYSON & CO | $6.888 | 420 | 0,00% | Ações |
| Continuum Advisory, LLC | $6.560 | 400 | 0,00% | Ações |
| MORGAN STANLEY | $6.462 | 394 | 0,00% | Ações |
| Duquesne Family Office LLC | $6.287 | 383.363 | 0,00% | Ações |
| HARBOUR INVESTMENTS, INC. | $5.936 | 362 | 0,00% | Ações |
| WELLS FARGO & COMPANY/MN | $4.920 | 300 | 0,00% | Ações |
| OSAIC HOLDINGS, INC. | $4.541 | 277 | 0,00% | Ações |
| Wilmington Savings Fund Society, FSB | $4.526 | 276 | 0,00% | Ações |
| NISA INVESTMENT ADVISORS, LLC | $3.280 | 200 | 0,00% | Ações |
| Farther Finance Advisors, LLC | $2.690 | 164 | 0,00% | Ações |
| HRT FINANCIAL LP | $2.479 | 151.197 | 0,00% | Ações |
| Federation des caisses Desjardins du Quebec | $2.378 | 145 | 0,00% | Ações |
| Silver Grove Financial Group, Inc. | $1.328 | 81 | 0,00% | Ações |
| Larson Financial Group LLC | $1.082 | 66 | 0,00% | Ações |
| Ascentis Wealth Management, LLC | $967 | 59 | 0,00% | Ações |
| SEI INVESTMENTS CO | $820 | 50 | 0,00% | Ações |
| Pinnacle Wealth Planning Services, Inc. | $656 | 40 | 0,00% | Ações |
| NATIONAL BANK OF CANADA /FI/ | $371 | 23 | 0,00% | Ações |
| Bell Investment Advisors, Inc | $345 | 21 | 0,00% | Ações |
| JPMORGAN CHASE & CO | $320 | 20 | 0,00% | Ações |
| Caitong International Asset Management Co., Ltd | $213 | 13 | 0,00% | Ações |
| TRUST CO OF TOLEDO NA /OH/ | $164 | 10 | 0,00% | Ações |
| Stone House Investment Management, LLC | $148 | 9 | 0,00% | Ações |
| BlackRock, Inc. | $33 | 2 | 0,00% | Ações |
Executivos da empresa 10 insiders · 4 diretores · 3 conselheiros
| Investidor com informação privilegiada | Função | Última atividade | Ações detidas | Compras 12m | Vendas 12m | Líquido 12m |
|---|---|---|---|---|---|---|
| Daniel Tasse | Chief Executive Officer | 20 de Novembro de 2023 A | — | 0 | 0 | $0 |
| Virginie Boucinha | Chief Financial Officer | 20 de Novembro de 2023 A | 19.000 | 0 | 0 | $0 |
| Sebastien Robitaille | Chief Financial Officer | 21 de Novembro de 2022 A | 36.500 | 0 | 0 | $0 |
| Pharis Mohideen | Chief Medical Officer | 29 de Julho de 2026 S | 144.531 | 0 | 1 | $-1.253 |
| Timothy E Morris | Conselheiro | 25 de Agosto de 2023 P | 12.000 | 0 | 0 | $0 |
| Daniel B Soland | Conselheiro | 1 de Agosto de 2023 P | 20.000 | 0 | 0 | $0 |
| Adora Ndu | — | 10 de Junho de 2021 P | — | 0 | 0 | $0 |
| Viviane Monges | — | 10 de Junho de 2021 P | — | 0 | 0 | $0 |
| Madduri Ravin Rao | — | 10 de Junho de 2021 P | — | 0 | 0 | $0 |
| Michel De Rosen | — | 10 de Junho de 2021 P | — | 0 | 0 | $0 |
Executivos de declarações SEC Formulário 3/4/5; líquido = apenas P/V de mercado aberto
Ativistas e proprietários de 5%+ 2 participações
Investidores que apresentaram o Schedule 13D da SEC — propriedade benéfica acima de 5% com a intenção de influenciar o emissor (participações ativistas, campanhas no conselho, M&A). Cada linha mostra o estado mais recente conhecido da posição desse declarante.
| Declarante | Declarado | Participação | Status | Propósito | Declaração |
|---|---|---|---|---|---|
| Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, Julian C. Baker, Felix J. Baker ×10 declarações | 14 de Janeiro de 2026 | 9,99% | Emenda | Investimento passivo | SEC |
| Bpifrance Participations S.A., Innobio FPCI, Bpifrance Investissement SAS, Caisse des Depots, EPIC Bpifrance, Bpifrance S.A. ×11 declarações | 7 de Janeiro de 2026 | 4,70% | Emenda | Investimento passivo | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Participação em ETFs Detido por 1 ETF
O peso reflete apenas participações diretas em ações (N-PORT); fundos alavancados ou baseados em derivativos podem deter exposição adicional a swaps não mostrada.
| Fundo | Peso | Unidades | Em | Fonte |
|---|---|---|---|---|
| APIE · Trust for Professional Managers | 0,00% | 2.245 NS | 31 de Maio de 2026 | N-PORT |